Eli Lilly and Company $LLY Shares Sold by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc trimmed its holdings in Eli Lilly and Company (NYSE:LLY) by 2.9% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 869,925 shares of the company’s stock after selling 25,975 shares during the period. Eli Lilly and Company accounts for about 1.2% of Ensign Peak Advisors Inc’s holdings, making the stock its 11th biggest holding. Ensign Peak Advisors Inc owned 0.09% of Eli Lilly and Company worth $678,133,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. Wealth Preservation Advisors LLC acquired a new position in Eli Lilly and Company during the 1st quarter worth about $27,000. Financial Gravity Companies Inc. acquired a new stake in Eli Lilly and Company during the second quarter worth approximately $31,000. Blume Capital Management Inc. lifted its holdings in shares of Eli Lilly and Company by 46.7% in the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after purchasing an additional 14 shares during the last quarter. IMG Wealth Management Inc. acquired a new position in shares of Eli Lilly and Company in the 2nd quarter valued at $35,000. Finally, TD Capital Management LLC boosted its stake in shares of Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after buying an additional 31 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Up 1.8%

Shares of NYSE LLY opened at $1,048.90 on Thursday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,055.59. The company has a market cap of $991.61 billion, a price-to-earnings ratio of 68.56, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock’s 50 day simple moving average is $844.09 and its 200 day simple moving average is $784.22.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping the consensus estimate of $6.42 by $0.60. The firm had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm’s revenue for the quarter was up 53.9% on a year-over-year basis. During the same period last year, the company earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Daiwa Capital Markets upped their price objective on Eli Lilly and Company from $700.00 to $940.00 in a report on Monday, November 10th. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. BMO Capital Markets lifted their price objective on Eli Lilly and Company from $930.00 to $1,100.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Scotiabank started coverage on Eli Lilly and Company in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $1,165.00 price target for the company. Finally, Loop Capital set a $950.00 target price on shares of Eli Lilly and Company in a research report on Monday, November 10th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $1,027.95.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.